News

Taiwan-based premier international contract development and manufacturing organization (CDMO) Bora Pharmaceuticals recently announced the establishment of Bora Biologics Co., Ltd., to focus on the development of bio-pharmaceuticals. Bora Biologics has investors Taishin Healthcare Limited Partnership and Dr. Allen Chao,...

Abzena, the leading Partner Research Organization (PRO) providing integrated discovery, development and manufacturing of biologics and antibody drug conjugates (ADCs) has announced the appointment of Dr. Petra Dieterich, DPhil, MBA, as scientific lead. Reporting to Abzena’s chief technology officer Dr....

DELIVER is the world's largest study of heart failure with intact ejection fraction. The DELIVER phase 3 trial produced favourable findings for AstraZeneca. It showed that Farxiga (dapagliflozin) reduced the primary outcome of cardiovascular death or deteriorating heart failure...

Ashfield Engage, part of UDG Healthcare has acquired PROPENSITY4 - a ‘smart data’ organization and leader in the healthcare insights and analytics arena. PROPENSITY4 integrates internal and external data assets and applies the right methodologies to derive detailed insight using...

Citius Pharmaceuticals, Inc., a late-stage biopharmaceutical company, announced that it has selected Biorasi, LLC (Biorasi), a global clinical research organization (CRO), to help expand the company's phase 3 Mino-Lok trial to additional sites outside the United States. If approved,...

It's a fact: EUROAPI debuted on the Euronext exchange two years and one pandemic after Sanofi announced plans to sell off its European pharma ingredients division. Even though the market as a whole was going down, shares of the...

Novartis has halted production of its two commercial radioligand treatments for cancer care just weeks after the FDA approved them. Novartis confirmed on May 5th that production of Lutathera, a neuroendocrine tumour medication, and Pluvicto, a newly approved prostate cancer...